Horizon Pharma to buy Hyperion Therapeutics

Horizon Pharma PLC has agreed to purchase Hyperion Therapeutics for $955.7 million in cash, in a move to expand its drug portfolio by adding two treatments for a rare metabolic condition.

The offer of $46 a share is a 7.6% premium over Hyperion’s

HPTX, -1.88%

 closing price of $42.74 a share on Friday. The deal is expected to add to earnings immediately and will contribute about $100 million in 2016 to earnings before interest, taxes, depreciation and amortization, or Ebitda, Horizon said.

Orphan diseases are rare conditions that haven’t been adopted by the pharmaceutical industry because there is little financial incentive to develop treatment. Ravicti and Buphenyl are treatments for those with urea cycle disorder, which affects about 2,100 people in the U.S. Net sales for the two drugs were $30.8 million and $113.6 million, respectively, in 2014.

The deal brings the number of Horizon’s

HZNP, +3.27%

 products to seven from five.

Horizon will pay for the deal in a combination of cash and $900 million in debt commitments.

An expanded version of this report appears at WSJ.com.

Source Article from http://www.marketwatch.com/bulletinredir.asp?guid=%7BCF0B0A87-CFF0-44EA-878A-A0E040885B12%7D&siteid=bulletrss
Horizon Pharma to buy Hyperion Therapeutics
pharma – Yahoo News Search Results
pharma – Yahoo News Search Results


メールアドレスが公開されることはありません。 * が付いている欄は必須項目です

次のHTML タグと属性が使えます: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>